MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-12-2026
Neoleukin Therapeutics EV - Enterprise Value 2011-2026 | NLTX
Annual EV - Enterprise Value Neoleukin Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -80.1 M | -111 M | -110 M | -33.8 M | 19.9 M | 509 M | 180 M | -19.3 M | 264 M | 311 M | 98 M | 82.3 M | -6.12 M | 51.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 509 M | -111 M | 82.5 M |
EV - Enterprise Value of other stocks in the Drug manufacturers industry
| Issuer | EV - Enterprise Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Endo International plc
ENDP
|
-710 M | - | - | $ 28.9 M |  Irlanda |
 |
Evoke Pharma
EVOK
|
-3.12 M | - | - | $ 36.6 M |  USA |
 |
Cumberland Pharmaceuticals
CPIX
|
126 M | $ 5.59 | -0.27 % | $ 83 M | USA |
 |
HEXO Corp.
HEXO
|
560 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-974 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
6.79 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-11 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
28.5 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
737 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
25.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Alimera Sciences
ALIM
|
197 M | - | - | $ 142 M | USA |
 |
Cronos Group
CRON
|
-1.35 M | $ 2.62 | -2.24 % | $ 1 B | Canada |
 |
Athenex
ATNX
|
209 M | - | -23.39 % | $ 1.76 M | USA |
 |
Harrow Health
HROW
|
2.21 B | $ 38.88 | 3.28 % | $ 1.43 B | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
756 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
16.7 B | - | - | $ 11.5 B | USA |
 |
Organogenesis Holdings
ORGO
|
408 M | $ 2.4 | 2.56 % | $ 304 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
457 M | - | -39.89 % | $ 27.7 M | USA |
 |
Pacira BioSciences
PCRX
|
1.68 B | $ 22.88 | -0.5 % | $ 1.06 B | USA |
 |
Canopy Growth Corporation
CGC
|
459 M | $ 0.97 | -2.78 % | $ 104 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
7.57 M | $ 1.13 | 3.21 % | $ 1.4 M | USA |
 |
Aurora Cannabis
ACB
|
330 M | $ 3.01 | -1.15 % | $ 165 M | Canada |
 |
Solid Biosciences
SLDB
|
616 M | $ 7.2 | 0.84 % | $ 630 M | USA |
 |
Jupiter Wellness
JUPW
|
3.7 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
671 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
146 M | $ 1.03 | -2.36 % | $ 98.2 M | Canada |
 |
Tilray
TLRY
|
1.96 B | $ 4.99 | 0.17 % | $ 3.08 B | Canada |
 |
Evolus
EOLS
|
467 M | $ 6.67 | -0.97 % | $ 430 M | USA |
 |
Sundial Growers
SNDL
|
-17.5 M | $ 1.43 | 0.35 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
1.04 B | $ 8.28 | -0.54 % | $ 443 M | USA |
 |
cbdMD
YCBD
|
4.51 M | $ 0.69 | 0.6 % | $ 2.78 M | USA |
 |
Veru
VERU
|
80.7 M | $ 3.1 | 3.33 % | $ 45.4 M | USA |
 |
Assertio Holdings
ASRT
|
238 M | $ 23.5 | 0.09 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
56.3 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
715 M | - | - | $ 1.42 B | USA |
 |
Bausch Health Companies
BHC
|
26.7 B | $ 5.0 | -1.19 % | $ 1.85 B | Canada |
 |
PetIQ
PETQ
|
280 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
251 M | $ 6.54 | -1.65 % | $ 258 M | USA |
 |
Recro Pharma
REPH
|
220 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
84.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
26.3 M | $ 4.17 | -1.54 % | $ 208 M | USA |
 |
PLx Pharma
PLXP
|
75 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
21.2 B | $ 16.34 | -0.88 % | $ 19 B | USA |
 |
Zomedica Corp.
ZOM
|
2.62 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-22.6 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
43.3 M | $ 0.66 | 5.01 % | $ 23.7 M | USA |
 |
Tricida
TCDA
|
555 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
10.7 M | $ 0.76 | 6.34 % | $ 3.26 M |  China |
 |
TherapeuticsMD
TXMD
|
26.3 M | $ 2.3 | 4.55 % | $ 26.6 M | USA |